Literature DB >> 1318937

Expression of the mouse mammary tumor virus ORF gene in cultured cells.

K Blöchlinger1, H Diggelmann.   

Abstract

We have recently shown that expression vectors harboring the open reading frame of the long terminal repeat region of mouse mammary tumor virus direct the synthesis of a product which acts as a superantigen in transgenic mice. The detection of the ORF protein has been hampered by the extremely low levels of expression observed in these mice, as estimated from the low levels of specific mRNA. To study the properties of the ORF protein, we attempted its expression in different cell types in culture. The experiments performed in yeast show that the ORF gene product is a glycoprotein of approximately 45 kDA. As expected from the derived primary sequence, the unglycosylated product made in the presence of tunicamycin has a molecular weight of 36 kDA. No secretion of the glycosylated protein was observed. Curiously, the full-length molecule was made in lower amounts than a truncated version which contains only the C-terminal half of the protein. Transfection experiments in different mammalian cells suggest that high expression of the ORF protein might have an adverse effect on survival of cells in culture.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1318937     DOI: 10.3109/08830189209053517

Source DB:  PubMed          Journal:  Int Rev Immunol        ISSN: 0883-0185            Impact factor:   5.311


  2 in total

1.  Identification of key amino acids of the mouse mammary tumor virus superantigen involved in the specific interaction with T-cell receptor V(beta) domains.

Authors:  F Baribaud; S Wirth; I Maillard; S Valsesia; H Acha-Orbea; H Diggelmann
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

2.  Regions of mouse mammary tumor virus superantigen involved in interaction with the major histocompatibility complex class II I-A molecule.

Authors:  Susanne Wirth; Annelyse Vessaz; Claude Krummenacher; Frédéric Baribaud; Hans Acha-Orbea; Heidi Diggelmann
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.